{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020229","form_type":"8-K","ticker":"FEED","cik":"0001326706","company_name":"ENvue Medical, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.870445+00:00","generated_at":"2026-06-01T19:35:28.252663+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NanoVibronix reports record Q1 revenue of $921K; operating loss $568K","bullets":["Q1 2024 revenue $921K, largest Q1 ever; operating loss $568K.","Cash $2.7M, inventory $2.6M; balance sheet strong.","GSA contract for VA sales effective May 1, 2024, expected to accelerate adoption.","UroShield RCT study at University of Michigan begins pilot phase (up to 30 patients).","PainShield adoption growing in VA and workers' comp markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020229","json":"https://secwatch.observer/filing/0001493152-24-020229.json","markdown":"https://secwatch.observer/filing/0001493152-24-020229.md","text":"https://secwatch.observer/filing/0001493152-24-020229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326706/000149315224020229/0001493152-24-020229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326706/000149315224020229/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T19:35:28.252663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}